Antigenic targets evaluated for CAR-T for pancreatic cancer in preclinical or clinical models notably include prostate stem cell antigen, mesothelin (MSLN), CEACAM7, CEA, HER2, Mucin-1, FAP, and others [256,257,258,259,260,261]. This evidence concerns the gene MUC1 and pancreatic neoplasm.